Non-Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast

The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year forecast period. Key therapies expected to fuel growth are the recently approved CAR T-cell therapies Yescarta (Gilead / Kite), Kymriah (Novartis), and Tecartus (Gilead / Kite), as well as novel, targeted agents Polivy (Roche) and Monjuvi (MorphoSys / Incyte). In addition, combinations incorporating the BTK inhibitors Imbruvica (Janssen) and Calquence (Acerta / AstraZeneca), the Bcl-2 inhibitor Venclexta / Venclyxto (AbbVie / Roche), and anti-CD20 monoclonal antibodies will enter the market, which will result in a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of the novel emerging therapies (bispecific antibody glofitamab (Roche), anti-CD19 ADC loncastuximab tesirine (ADC Therapeutics), anti-CD30 ADC Adcetris (Takeda / Seattle Genetics), and selective inhibitor of nuclear export Xpovio (Karyopharm) will further fragment the R/R DLBCL patient setting and create intense competition. Offsetting this market growth will be the biosimilar erosion expected for rituximab IV and SC, as well as the generic erosion of Celgene’s Revlimid and Janssen's Imbruvica. Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in underserved patient segments.

Questions Answered

  • Which emerging therapies are the most promising in NHL, and what patient populations will they target? What will be their impact on the NHL market?
  • How will market share for rituximab change over the ten-year forecast period as a result of biosimilar entry? Will Roche / Genentech’s Gazyva / Gazyvaro and Rituxan Hycela / MabThera SC be able to minimize the impact of biosimilar erosion of branded rituximab?
  • The NHL therapy market will experience robust growth through 2029. What factors are driving growth in the NHL market? Which drug class will dominate the treatment of NHL? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?

Content Highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL).

Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL/SLL, DLBCL, and MCL.

Emerging therapies: Phase I/II: 19 drugs; Phase III / PR: 9 drugs.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q3 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
      • Q3 2020
        • September 2020
      • Q2 2020
        • May 2020
    • Key Findings
      • Non-Hodgkin's Lymphoma - Key Findings
        • May 2020
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for Non-Hodgkin's Lymphoma in 2019
        • Market Share of Drug Classes for Non-Hodgkin's Lymphoma in 2029
        • Positioning of Key Therapies in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma in the United States: 2019-2029
        • Positioning of Key Therapies in Diffuse Large B-Cell Lymphoma in the United States: 2019-2029
        • Positioning of Key Therapies in Follicular Lymphoma in the United States: 2019-2029
        • Positioning of Key Therapies in Mantle Cell Lymphoma in the United States: 2019-2029
        • Non-Hodgkin's Lymphoma SWOT Analysis
        • Current Therapies with Sales Potential in Non-Hodgkin's Lymphoma: Population Positioning
        • Emerging Therapies with Sales Potential in Non-Hodgkin's Lymphoma: Population Positioning
      • COVID-19: Areas of Potential Forecast Impact
        • COVID-19: Areas of Potential Forecast Impact
        • Expert Insights: COVID-19 Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for NHL?
        • What Factors Are Constraining the Market for NHL?
        • Drug-Treatable Population Share and Major-Market Sales Share for CLL / SLL: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share for CLL / SLL: 2029
        • Drug-Treatable Population Share and Major-Market Sales Share for DLBCL: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share for DLBCL: 2029
        • Drug-Treatable Population Share and Major-Market Sales Share for FL: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share for FL: 2029
        • Drug-Treatable Population Share and Major-Market Sales Share for MCL: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share for MCL: 2029
        • Major-Market Non-Hodgkin's Lymphoma Sales by Subpopulation: 2019-2029
        • Key Non-Hodgkin's Lymphoma Therapies with Major-Market Sales Exceeding $1.0 Billion in 2029
      • Segment-Specific Trends
        • Patient-Share Dynamics of Key Drug Classes in First-Line CLL / SLL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in First-Line CLL / SLL in the United States: 2019-2029
        • Sales of Key Therapies for First-Line CLL / SLL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Second-Line CLL / SLL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Third-Line CLL / SLL in the United States: 2019-2029
        • Sales of Key Therapies for Second-Line CLL / SLL in the United States: 2019-2029
        • Sales of Key Therapies for Third-Line CLL / SLL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in First-Line DLBCL in the United States: 2019-2029
        • Sales of Key Therapies for First-Line DLBCL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Second-Line DLBCL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Third-Line DLBCL in the United States: 2019-2029
        • Sales of Key Therapies for Second-Line DLBCL in the United States: 2019-2029
        • Sales of Key Therapies for Third-Line DLBCL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in First-Line FL in the United States: 2019-2029
        • Sales of Key Therapies for First-Line FL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Second-Line FL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Third-Line FL in the United States: 2019-2029
        • Sales of Key Therapies for Second-Line FL in the United States: 2019-2029
        • Sales of Key Therapies for Third-Line FL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in First-Line MCL in the United States: 2019-2029
        • Sales of Key Therapies for First-Line MCL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Second-Line MCL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Third-Line MCL in the United States: 2019-2029
        • Sales of Key Therapies for Second-Line MCL in the United States: 2019-2029
        • Sales of Key Therapies for Third-Line MCL in the United States: 2019-2029
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Pathophysiology
          • Select Risk Factors Associated with Non-Hodgkin's Lymphoma
          • International Prognostic Index Scoring for Patients of All Ages
          • Revised International Prognostic Index Score in Patients Treated with R-CHOP
          • Select Biomarkers for Non-Hodgkin's Lymphoma Subpopulations Predicting Clinical Outcome
        • Staging and Classification
          • Staging of Non-Hodgkin's Lymphoma
          • Revised Ann Arbor Staging System for Primary Nodal Lymphomas
          • The Binet Staging System for CLL / SLL
          • The Rai Staging System for CLL / SLL
          • Normal B-Cell Development and Cellular Origin of B-Cell Malignancies
        • Key Pathways and Drug Targets
          • Key Drug Targets for Non-Hodgkin's Lymphoma
          • Immune Checkpoint Activation and Pathways
      • Epidemiology
        • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Incidence of NHL
            • Number of Diagnosed Incident Cases of NHL in the Major Pharmaceutical Markets by Subtype: 2019-2029
            • Disease Definition
            • Methods
            • Sources Used for Molecular Subtype of De Novo DLBCL Incident Cases
            • Number of Diagnosed Incident Cases of De Novo DLBCL in the Major Pharmaceutical Markets by Molecular Subtype: 2019-2029
            • Definition
            • Methods
            • Sources Used for Transformed Incidence from FL to DLBCL
            • Number of Diagnosed Incident Cases of Transformed Incidence from FL to DLBCL in the Major Pharmaceutical Markets: 2019-2029
            • Definition
            • Methods
            • Sources Used for Transformed Incidence from CLL to DLBCL
            • Number of Diagnosed Incident Cases of Transformed Incidence from CLL to DLBCL in the Major Pharmaceutical Markets: 2019-2029
            • FL Patient Flow
            • Number of Drug-Treatable Cases of FL in the Major Pharmaceutical Markets by Line: 2019-2029
            • DLBCL Drug-Treatable Population
            • DLBCL Patient Flow
            • Number of Drug-Treatable Cases of DLBCL in the Major Pharmaceutical Markets by Line: 2019-2029
            • MCL Drug-Treatable Population
            • MCL Patient Flow
            • Number of Drug-Treatable Cases of MCL in the Major Pharmaceutical Markets by Line: 2019-2029
            • CLL / SLL Drug-Treatable Population
            • CLL / SLL Patient Flow
            • Number of Drug-Treatable Cases of CLL / SLL in the Major Pharmaceutical Markets by Line: 2019-2029
            • Number of Drug-Treated Cases of FL in the Major Pharmaceutical Markets by Line: 2019-2029
            • Number of Drug-Treated Cases of DLBCL in the Major Pharmaceutical Markets by Line: 2019-2029
            • Number of Drug-Treated Cases of MCL in the Major Pharmaceutical Markets by Line: 2019-2029
            • Number of Drug-Treated Cases of CLL / SLL in the Major Pharmaceutical Markets by Line: 2019-2029
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for NHL
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for NHL
              • Current Treatments Used for NHL
              • Market Events Impacting the Use of Key Current Therapies in NHL
              • Advantages and Disadvantages of Rituximab (Rituxan / MabThera)
              • Ongoing Clinical Development of Rituximab (Rituxan / MabThera)
              • Key Ongoing Clinical Trials of Rituximab (Rituxan / MabThera) in the Treatment of NHL
              • Expert Insight: Rituximab (Rituxan / MabThera)
              • Advantages and Disadvantages of Gazyva / Gazyvaro
              • Key Results from Select Clinical Trials Investigating Gazyva / Gazyvaro for the Treatment of NHL
              • Ongoing Clinical Development of Gazyva / Gazyvaro
              • Key Ongoing Clinical Trials of Gazyva / Gazyvaro in the Treatment of NHL
              • Expert Insight: Gazyva / Gazyvaro
              • Key Results from Select Clinical Trials Investigating Monjuvi for the Treatment of NHL
              • Ongoing Clinical Development of Monjuvi
              • Key Ongoing Clinical Trials of Monjuvi in the Treatment of NHL
              • Expert Insight: Monjuvi
              • Advantages and Disadvantages of Arzerra
              • Ongoing Clinical Development of Arzerra
              • Expert Insight: Arzerra
              • Advantages and Disadvantages of Campath / MabCampath
              • Advantages and Disadvantages of Polivy
              • Key Results from Select Clinical Trials Investigating Polivy for the Treatment of NHL
              • Analysis of the Clinical Development Program for Polivy
              • Key Ongoing Clinical Trials of Polivy in the Treatment of NHL
              • Expert Insight: Polivy
              • Key Results from Select Clinical Trials Investigating Zynlonta for the Treatment of NHL
              • Ongoing Clinical Development of Zynlonta
              • Key Ongoing Clinical Trials of Zynlonta in the Treatment of NHL
              • Expert Insight: Zynlonta
              • Advantages and Disadvantages of Venclexta / Venclyxto
              • Key Results from Select Clinical Trials Investigating Venclexta / Venclyxto for the Treatment of NHL
              • Ongoing Clinical Development of Venclexta / Venclyxto
              • Key Ongoing Clinical Trials of Venclexta / Venclyxto in the Treatment of NHL
              • Expert Insight: Venclexta / Venclyxto
              • Advantages and Disadvantages of Revlimid (Lenalidomide)
              • Key Results from Select Clinical Trials Investigating Revlimid (Lenalidomide) for the Treatment of NHL
              • Ongoing Clinical Development of Revlimid (Lenalidomide)
              • Key Ongoing Phase III Clinical Trials of Revlimid (Lenalidomide) in the Treatment of NHL
              • Advantages and Disadvantages of Velcade
              • Expert Insight: Velcade
              • Advantages and Disadvantages of Torisel
              • Advantages and Disadvantages of Imbruvica
              • Key Results from Select Clinical Trials Investigating Imbruvica for the Treatment of NHL
              • Key Ongoing Phase III Clinical Trials of Imbruvica in the Treatment of NHL
              • Expert Insight: Imbruvica
              • Advantages and Disadvantages of Calquence
              • Key Results from Select Clinical Trials Investigating Calquence for the Treatment of NHL
              • Ongoing Clinical Development of Calquence
              • Key Ongoing Clinical Trials of Calquence in the Treatment of NHL
              • Expert Insight: Calquence
              • Key Results from Select Clinical Trials Investigating Brukinsa for the Treatment of NHL
              • Ongoing Clinical Development of Brukinsa
              • Key Ongoing Clinical Trials of Brukinsa in the Treatment of NHL
              • Expert Insight: Brukinsa
              • Advantages and Disadvantages of Zydelig
              • Key Results from Select Clinical Trials Investigating Zydelig for the Treatment of NHL
              • Ongoing Clinical Development of Zydelig
              • Key Ongoing Clinical Trials of Zydelig in the Treatment of NHL
              • Expert Insight: Zydelig
              • Advantages and Disadvantages of Aliqopa
              • Key Results from Select Clinical Trials Investigating Aliqopa for the Treatment of NHL
              • Ongoing Clinical Development of Aliqopa
              • Key Ongoing Clinical Trials of Aliqopa in the Treatment of NHL
              • Expert Insight: Aliqopa
              • Advantages and Disadvantages of Copiktra
              • Key Results from Select Clinical Trials Investigating Copiktra for the Treatment of NHL
              • Ongoing Clinical Development of Copiktra
              • Key Ongoing Clinical Trials of Copiktra in the Treatment of NHL
              • Expert Insight: Copiktra
              • Key Results from Select Clinical Trials Investigating Ukoniq for the Treatment of NHL
              • Ongoing Clinical Development of Ukoniq
              • Key Ongoing Clinical Trials of Ukoniq in the Treatment of NHL
              • Expert Insight: Ukoniq
              • Advantages and Disadvantages of Bendamustine
              • Expert Insight: Bendamustine
              • Advantages and Disadvantages of Pixuvri
              • Clinical Development of Pixuvri
              • COVID-19: Areas of Potential Impact on CAR T-Cell Therapy
              • Advantages and Disadvantages of Yescarta
              • Key Results from Select Clinical Trials Investigating Yescarta for the Treatment of NHL
              • Ongoing Clinical Development of Yescarta
              • Key Ongoing Clinical Trials of Yescarta in the Treatment of NHL
              • Expert Insight: Yescarta
              • Advantages and Disadvantages of Kymriah
              • Key Results from Select Clinical Trials Investigating Kymriah for the Treatment of NHL
              • Ongoing Clinical Development of Kymriah
              • Key Ongoing Clinical Trials of Kymriah in the Treatment of NHL
              • Expert Insight: Kymriah
              • Tecartus
              • Key Results from Select Clinical Trials Investigating Tecartus for the Treatment of NHL
              • Ongoing Clinical Development of Tecartus
              • Key Ongoing Clinical Trials of Tecartus in the Treatment of NHL
              • Expert Insight: Tecartus
              • Key Results from Select Clinical Trials Investigating Breyanzi for the Treatment of NHL
              • Ongoing Clinical Development of Breyanzi
              • Key Ongoing Clinical Trials of Breyanzi in the Treatment of NHL
              • Expert Insight: Breyanzi
              • Advantages and Disadvantages of Keytruda
              • Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of NHL
              • Ongoing Clinical Development of Keytruda
              • Key Ongoing Clinical Trials of Keytruda in the Treatment of NHL
              • Expert Insight: Keytruda
              • Tazverik
              • Key Results from Select Clinical Trials Investigating Tazverik for the Treatment of NHL
              • Ongoing Clinical Development of Tazverik
              • Key Ongoing Clinical Trials of Tazverik in the Treatment of NHL
              • Expert Insight: Tazverik
              • Key Results from Select Clinical Trials Investigating Xpovio for the Treatment of NHL
              • Ongoing Clinical Development of Xpovio
              • Key Ongoing Clinical Trials of Xpovio in the Treatment of NHL
              • Expert Insight: Xpovio
            • Medical Practice
              • First-Line CLL/SLL Drug-Treatable Population
              • First-Line DLBCL Drug-Treatable Population
              • First-Line FL Drug-Treatable Population
              • First-Line MCL Drug-Treatable Population
              • Relapsed / Refractory CLL/SLL Drug-Treatable Population
              • Relapsed / Refractory DLBCL Drug-Treatable Population
              • Relapsed / Refractory FL Drug-Treatable Population
              • Relapsed / Refractory MCL Drug-Treatable Population
              • NHL Treatment Guidelines by Market
              • Patient Characteristics Influencing Drug Selection in NHL
              • Treatment Decision Tree for FL: United States
              • Treatment Decision Tree for CLL/SLL: United States
              • Treatment Decision Tree for DLBCL: United States
              • Treatment Decision Tree for MCL: United States
              • Treatment Decision Tree for FL: Europe
              • Treatment Decision Tree for CLL/SLL: Europe
              • Treatment Decision Tree for DLBCL: Europe
              • Treatment Decision Tree for MCL: Europe
              • Treatment Decision Tree for FL: Japan
              • Treatment Decision Tree for CLL/SLL: Japan
              • Treatment Decision Tree for DLBCL: Japan
              • Treatment Decision Tree for MCL: Japan
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in Non-Hodgkin's Lymphoma
            • Top Unmet Needs in Non-Hodgkin's Lymphoma: Current and Future Attainment
            • Expert Insight: Unmet Need in Non-Hodgkin's Lymphoma
          • Emerging Therapies
            • Key Findings
              • Pipeline Trends in NHL
            • Key Emerging Therapies
              • Notable Developments Among Key Emerging Therapies for NHL
              • Key Therapies in Development for NHL
              • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of NHL
              • Key Results from Select Clinical Trials Investigating Enzastaurin for the Treatment of NHL
              • Key Ongoing Clinical Trials of Enzastaurin in the Treatment of NHL
              • Analysis of the Clinical Development Program for Enzastaurin
              • Expert Insight: Enzastaurin
              • Expectations for Market Authorization and Sales Opportunity of Enzastaurin in NHL
              • Key Results from Select Clinical Trials Investigating Ublituximab for the Treatment of NHL
              • Key Ongoing Clinical Trials of Ublituximab in the Treatment of NHL
              • Analysis of the Clinical Development Program for Ublituximab
              • Expert Insight: Ublituximab
              • Expectations for Market Authorization and Sales Opportunity of Ublituximab in NHL
              • Key Results from Select Clinical Trials Investigating Glofitamab for the Treatment of NHL
              • Key Ongoing Clinical Trials of Glofitamab in the Treatment of NHL
              • Analysis of the Clinical Development Program for Glofitamab
              • Expert Insight: Glofitamab
              • Expectations for Market Authorization and Sales Opportunity of Glofitamab in NHL
              • Key Results from Select Clinical Trials Investigating Blincyto for the Treatment of NHL
              • Key Ongoing Clinical Trials of Blincyto in the Treatment of NHL
              • Analysis of the Clinical Development Program for Blincyto
              • Expert Insight: Blincyto
              • Expectations for Market Authorization and Sales Opportunity of Blincyto in NHL
              • Key Results from Select Clinical Trials Investigating Epcoritamab for the Treatment of NHL
              • Key Ongoing Clinical Trials of Epcoritamab in the Treatment of NHL
              • Analysis of the Clinical Development Program for Epcoritamab
              • Expectations for Market Authorization and Sales Opportunity of Epcoritamab in NHL
              • Key Results from Select Clinical Trials Investigating Mosunetuzumab for the Treatment of NHL
              • Key Ongoing Clinical Trials of Mosunetuzumab in the Treatment of NHL
              • Analysis of the Clinical Development Program for Mosunetuzumab
              • Expectations for Market Authorization and Sales Opportunity of Mosunetuzumab in NHL
              • Key Results from Select Clinical Trials Investigating Adcetris for the Treatment of NHL
              • Key Ongoing Clinical Trials of Adcetris in the Treatment of NHL
              • Analysis of the Clinical Development Program for Adcetris
              • Expert Insight: Adcetris
              • Expectations for Market Authorization and Sales Opportunity of Adcetris in NHL
              • Key Results from Select Clinical Trials Investigating Opdivo for the Treatment of NHL
              • Key Ongoing Clinical Trials of Opdivo in the Treatment of NHL
              • Analysis of the Clinical Development Program for Opdivo
              • Expert Insight: Opdivo
              • Expectations for Market Authorization and Sales Opportunity of Opdivo in NHL
              • Key Results from Select Clinical Trials Investigating Pirtobrutinib for the Treatment of NHL
              • Key Ongoing Clinical Trials of Pirtobrutinib in the Treatment of NHL
              • Analysis of the Clinical Development Program for Pirtobrutinib
              • Expectations for Market Authorization and Sales Opportunity of Pirtobrutinib in NHL
              • Key Results from Select Clinical Trials Investigating Parsaclisib for the Treatment of NHL
              • Key Ongoing Clinical Trials of Parsaclisib in the Treatment of NHL
              • Analysis of the Clinical Development Program for Parsaclisib
              • Expectations for Market Authorization and Sales Opportunity of Parsaclisib in NHL
              • Zandelisib
              • Key Results from Select Clinical Trials Investigating Zandelisib for the Treatment of NHL
              • Key Ongoing Clinical Trials of Zandelisib in the Treatment of NHL
              • Analysis of the Clinical Development Program for Zandelisib
              • Expectations for Market Authorization and Sales Opportunity of Zandelisib in NHL
              • Onureg (Oral Azacitidine)
              • Key Results from Select Clinical Trials Investigating Onureg (Oral Azacitidine) for the Treatment of NHL
              • Key Ongoing Clinical Trials of Onureg (Oral Azacitidine) in the Treatment of NHL
              • Analysis of the Clinical Development Program for Onureg (Oral Azacitidine)
              • Expectations for Market Authorization and Sales Opportunity of Onureg (Oral Azacitidine) in NHL
            • Early-Phase Pipeline Analysis
              • Select Compounds in Early-Phase Development for NHL
          • Access & Reimbursement Overview
            • Region-Specific Reimbursement Practices
              • Key Market Access Considerations in NHL: United States
              • General Reimbursement Environment: United States
              • Key Market Access Considerations in NHL: EU5
              • General Reimbursement Environment: EU5
              • Key Market Access Considerations in NHL: Japan
              • General Reimbursement Environment: Japan
          • Appendix
            • Brands, Marketers, and Generic Availability of Current Therapies Used for NHL by Market
            • Non-Hodgkin's Lymphoma Bibliography

        launch Related Market Assessment Reports